Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Wahl, M. Kunz, Aris Moschovitis, T. Nageh, M. Schwerzmann, C. Seiler, Heinrich Mattle, S. Windecker, B. Meier (2007)
Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolismHeart, 94
G. Fischer, J. Stieh, A. Uebing, U. Hoffmann, G. Morf, H. Kramer (2003)
Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patientsHeart, 89
F. Krizanic, H. Sievert, D. Pfeiffer, T. Konorza, M. Ferrari, H. Figulla (2008)
Clinical evaluation of a novel occluder device (Occlutech®) for percutaneous transcatheter closure of patent foramen ovale (PFO)Clinical Research in Cardiology, 97
F. Krizanic, H. Sievert, D. Pfeiffer, T. Konorza, M. Ferrari, Z. Hijazi, C. Jung, A. Lauten, H. Figulla (2010)
The Occlutech Figulla PFO and ASD occluder: a new nitinol wire mesh device for closure of atrial septal defects.The Journal of invasive cardiology, 22 4
M. Campbell (1970)
Natural history of atrial septal defect.British Heart Journal, 32
Post (2006)
Comparison of outcome and complications using different types of devices for percutaneous closure of a secundum atrial septal defect in adults: A single-center experienceCatheter Cardiovasc Interv, 67
M. Post, K. Deyk, W. Budts (2005)
Percutaneous closure of a patent foramen ovale: single-centre experience using different types of devices and mid-term outcomeActa Cardiologica, 60
A. Paç, T. Polat, Ilker Çetin, M. Oflaz, Şevket Balli (2009)
Figulla ASD occluder versus Amplatzer Septal Occluder: a comparative study on validation of a novel device for percutaneous closure of atrial septal defects.Journal of interventional cardiology, 22 6
O. Soliman, M. Geleijnse, F. Meijboom, A. Nemes, O. Kamp, P. Nihoyannopoulos, N. Masani, S. Feinstein, F. Cate (2007)
The use of contrast echocardiography for the detection of cardiac shunts.European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 8 3
J. Alaeddini, G. Feghali, S. Jenkins, S. Ramee, C. White, F. Abi-Samra (2006)
Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale.The Journal of invasive cardiology, 18 8
P. Hagen, D. Scholz, W. Edwards (1984)
Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts.Mayo Clinic proceedings, 59 1
A. Wahl, U. Krumsdorf, B. Meier, H. Sievert, S. Ostermayer, K. Billinger, M. Schwerzmann, U. Becker, C. Seiler, M. Arnold, H. Mattle, S. Windecker (2005)
Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients.Journal of the American College of Cardiology, 45 3
S. Windecker, A. Wahl, T. Chatterjee, A. Garachemani, Franz Eberli, C. Seiler, B. Meier (2000)
Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events.Circulation, 101 8
M. Braun, V. Gliech, A. Boscheri, S. Schoen, G. Gahn, H. Reichmann, M. Haass, R. Schraeder, R. Strasser (2004)
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems.European heart journal, 25 5
J. Mašura, P. Gavora, T. Podnar (2005)
Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders.Journal of the American College of Cardiology, 45 4
T. King, N. Mills (1974)
Nonoperative closure of atrial septal defects.Surgery, 75 3
M. Gent, M. Post, R. Snijder, M. Swaans, H. Plokker, C. Westermann, T. Overtoom, J. Mager (2009)
Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy?Chest, 135 5
R. Craig, A. Selzer (1968)
Natural History and Prognosis of Atrial Septal DefectCirculation, 37
Braun (2004)
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systemsEur Heart J, 25
P. Khairy, C. O'Donnell, M. Landzberg (2003)
Transcatheter Closure versus Medical Therapy of Patent Foramen Ovale and Presumed Paradoxical ThromboemboliAnnals of Internal Medicine, 139
P. Lechat, J. Mas, G. Lascault, P. Loron, M. Theard, M. Klimczac, G. Drobinski, D. Thomas, Y. Grosgogeat (1988)
Prevalence of patent foramen ovale in patients with stroke.The New England journal of medicine, 318 18
M. Taaffe, E. Fischer, A. Baranowski, N. Majunke, C. Heinisch, M. Leetz, R. Hein, Y. Bayard, F. Büscheck, M. Reschke, Ilona Hoffmann, N. Wunderlich, N. Wilson, H. Sievert (2008)
Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder).The American journal of cardiology, 101 9
M. Post, M. Suttorp, W. Jaarsma, H. Plokker (2006)
PEDIATRIC AND CONGENITAL HEART DISEASE Original Studies Comparison of Outcome and Complications Using Different Types of Devices for Percutaneous Closure of a Secundum Atrial Septal Defect in Adults: A Single-Center Experience
B. Branden, M.C. Post, W. Jaarsma, J. Berg, M. Suttorp (2009)
New bioabsorbable septal repair implant for percutaneous closure of a patent foramen ovale: Short‐term results of a single‐centre experienceCatheterization and Cardiovascular Interventions, 74
C. Spies, Abha Khandelwal, I. Timmermanns, R. Schräder (2008)
Incidence of atrial fibrillation following transcatheter closure of atrial septal defects in adults.The American journal of cardiology, 102 7
F. Krizanic, M. Sigler, H. Figulla (2009)
Transvenous Closure of Patent Foramen Ovale: Preliminary Results with a New Self-Expanding Nitinol Wire Mesh in a Swine ModelCardiology Research and Practice, 2009
S. Maffè, P. Dellavesa, F. Zenone, A. Paino, P. Paffoni, A. Perucca, D. Kozel, Fabiana Signorotti, M. Bielli, U. Parravicini, N. Pardo, Lorenzo Cucchi, A. Aymele, M. Zanetta (2010)
Transthoracic second harmonic two- and three-dimensional echocardiography for detection of patent foramen ovale.European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 11 1
N. Bridges, W. Hellenbrand, L. Latson, J. Filiano, J. Newburger, J. Lock (1992)
Transcatheter Closure of Patent Foramen Ovale After Presumed Paradoxical EmbolismCirculation, 86
Z. Du, Z. Hijazi, C. Kleinman, N. Silverman, K. Larntz (2002)
Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial.Journal of the American College of Cardiology, 39 11
(2010)
Figulla patent foramen ovale occluder vs . Amplatzer patent foramen ovale oc - cluder : A single - centre experience comparing both devices for percutaneous closure of patent foramen ovale
Background: The Occlutech Figulla Occluder is a new innovative device for percutaneous closure of a patent foramen ovale (PFO) and an atrial septum defect (ASD). We describe the safety and efficacy of this new device at 6‐month follow‐up. Methods: All 82 consecutive patients (51% female, mean age 49.0 ± 13.6 years) who underwent percutaneous PFO (n = 48) or ASD (n = 34) closure between October 2008 and October 2009 were included. Results: Implantation success was 100%. The in‐hospital complications were two new onset supraventricular tachycardia (SVT) (2.4%, both ASD patients), nine minimal groin hematoma's (11.0%, 4 PFO and 5 ASD patients), and one transient ST elevation during the procedure (1.2%, ASD patient). During 6 months follow‐up (n = 79), no major complications or reoccurrences of cerebral thrombo‐embolic events did occur. Seven patients (8.9%, 6 PFO and 1 ASD patient) experienced a new SVT. One patient developed a recurrent cerebral hemorrhage 5 months after ASD closure, which appeared not to be related to the procedure. Using contrast transthoracic echocardiography 6 months after PFO closure (n = 45), a residual shunt was present in 30.2% of the patients (small 25.6%, moderate 4.6%, severe 0%). In the ASD group (n = 34), a residual shunt was observed in 32.5% (small 17.7%, moderate 14.7%, severe 2.9%). Conclusion: The Occlutech Figulla Occluder appears to be easy to use, effective, and safe for percutaneous closure of PFO and ASD. We report a low complication rate but a relative high percentage of small residual shunts 6 months after closure. (J Interven Cardiol 2011;24:264–270)
Journal of Interventional Cardiology – Wiley
Published: Jun 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.